




12-12-01

JC10 Rec'd PCT/PTO 07 DEC/2001

OCT

FORM PTO-1390 (REV. 9-2001)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	
TRANSMISSION LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		ATTORNEY'S DOCKET NUMBER	
		59131-A PCT-US/JPW/FHB	
U.S. APPLICATION NO. (If known, see 37 CFR 1.5) Not Yet Known		PRIORITY DATE CLAIMED 10/018169	
INTERNATIONAL APPLICATION NO. PCT/US00/15621		INTERNATIONAL FILING DATE 7 June 2000	
TITLE OF INVENTION Gene Endoding NADE, p57NTR-Associated Cell Death Executor and Uses Thereof			
APPLICANT(S) FOR DO/EO/US The Trustees of Columbia University In the City of New York			
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:			
<p>1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.</p> <p>2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.</p> <p>3. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.</p> <p>4. <input checked="" type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (Article 31).</p> <p>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))</p> <ol style="list-style-type: none"> <input checked="" type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau). (courtesy copy) <input type="checkbox"/> has been communicated by the International Bureau. <input checked="" type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). <p>6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).</p> <ol style="list-style-type: none"> <input type="checkbox"/> is attached hereto. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4). <p>7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))</p> <ol style="list-style-type: none"> <input checked="" type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau). (courtesy copy) <input checked="" type="checkbox"/> have been communicated by the International Bureau. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. <input type="checkbox"/> have not been made and will not be made. <p>8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</p> <p>9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). (unsigned)</p> <p>10. <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</p> <p>Items 11 to 20 below concern document(s) or information included:</p> <p>11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</p> <p>12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</p> <p>13. <input checked="" type="checkbox"/> A FIRST preliminary amendment.</p> <p>14. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.</p> <p>15. <input type="checkbox"/> A substitute specification.</p> <p>16. <input type="checkbox"/> A change of power of attorney and/or address letter.</p> <p>17. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.</p> <p>18. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4).</p> <p>19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).</p> <p>20. <input checked="" type="checkbox"/> Other items or information: Courtesy copy of Notice Informing Applicant of the Communication of the International Application to the Designated Offices, PCT Request, PCT Demand, Written Opinion, Amendment In Reply To 31 August 2001 Written Opinion, Statement in Accordance with 37 C.F.R. 1.821(f), and Small Entity Declaration from U.S. parent application, 1 loose duplicate set of formal drawings (32pp), and an Express Mail Certificate of Mailing bearing Label No. EJ 700 080 263 US dated December 7, 2001.</p>			

U.S. APPLICATION NO. (if known) <small>37 CFR 1.15</small> Not Yet Known	INTERNATIONAL APPLICATION NO. PCT/US00/15621	ATTORNEY'S DOCKET NUMBER 59131-A-PCT-US/JPW		
107018169		CALCULATIONS PTO USE ONLY		
<p>21. <input checked="" type="checkbox"/> The following fees are submitted:</p> <p>BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)):</p> <p>Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$1040.00</p> <p>International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$890.00</p> <p>International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$740.00</p> <p>International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$710.00</p> <p>International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00</p>				
ENTER APPROPRIATE BASIC FEE AMOUNT =		\$ 710.00		
<p>Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).</p>		\$ 0.00		
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$
Total claims	47 - 20 =	27	x \$18.00	\$ 486.00
Independent claims	31 - 3 =	28	x \$84.00	\$2352.00
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$280.00	\$ 0.00
TOTAL OF ABOVE CALCULATIONS =		\$3548.00		
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.		\$1774.00		
SUBTOTAL =		\$1774.00		
<p>Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).</p>		\$ 0.00		
TOTAL NATIONAL FEE =		\$1774.00		
<p>Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property</p>		+ \$ 0.00		
TOTAL FEES ENCLOSED =		\$1774.00		
		Amount to be refunded:		\$
		charged:		\$
<p>a. <input checked="" type="checkbox"/> A check in the amount of \$ 1774.00 to cover the above fees is enclosed.</p> <p>b. <input type="checkbox"/> Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed.</p> <p>c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 03-3125. A duplicate copy of this sheet is enclosed.</p> <p>d. <input type="checkbox"/> Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.</p>				
<p>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.</p>				
<p>SEND ALL CORRESPONDENCE TO:</p> <p>John P. White Esq. Reg. No. 28,678 Cooper & Dunham LLP 1185 Avenue of the Americas New York, NY 10036</p>				
<p> SIGNATURE John P. White NAME 28,678 REGISTRATION NUMBER </p>				

10/018169

J605 Rec'd PCT/US 07 DEC 2001

Dkt. 59131-A-PCT-US/JPW/FHB

IN THE UNITED STATES DESIGNATED ELECTED OFFICE (DO/EO/US)

Applicants : Taka-Aki Sato

International
Application No. : PCT/US00/15621

Filed : 7 June 2000

For : GENE ENCODING NADE, P75^{NTR}-ASSOCIATED
CELL DEATH EXECUTOR AND USES THEREOF

1185 Avenue Of The Americas
New York, New York 10036
December 7, 2001


Assistant Commissioner for Patents
P.O. Box 2327
Arlington, VA 22202
Attn: DO/EO/US

EXPRESS MAIL CERTIFICATE OF MAILING
FOR ABOVE-IDENTIFIED APPLICATION

Express Mail mailing label number: EJ 700 080 263 US

Date of Deposit: December 7, 2001

I hereby certify that this paper or fee is being deposited with the
United States Postal Service "Express Mail Post Office to Addressee"
service under 37 C.F.R. §1.10 on the date indicated above and is
addressed to the Assistant Commissioner for Patents and Trademarks,
Washington, D.C. 20231.


Printed Name: John P. White

Respectfully submitted,


John P. White

Reg. No. 28,678
Attorney for Applicants
Cooper & Dunham LLP
1185 Ave of the Americas
New York, New York 10036
(212) 278-0400